Yes, radiation therapy does shrink the prostate. Studies using MRI measurements show an average 17% reduction in prostate volume within about eight months of treatment, with most of the shrinkage happening in the first two months. When radiation is combined with hormone therapy, the total reduction can reach 30% to 50%.
How Radiation Causes Shrinkage
Radiation damages the DNA inside cells, which prevents them from dividing and eventually causes them to die. In the prostate, this process affects both cancerous and normal tissue within the treatment field. As damaged cells break down and the body clears them away, the gland gradually gets smaller. In some cases, radiation can temporarily cause mild swelling due to inflammation before the shrinkage begins.
Over the long term, radiated tissue undergoes more permanent changes. Blood vessels in the treated area narrow and become less functional, leaving the tissue with reduced blood flow and oxygen. This leads to a process called fibrosis, where normal tissue is slowly replaced by scar-like tissue. These changes are part of why the prostate continues to shrink for months after treatment ends, not just during the radiation itself.
How Much the Prostate Shrinks
The degree of shrinkage depends on whether radiation is used alone or alongside hormone therapy. With radiation alone, one study tracking prostate volume on MRI found the gland shrank from an average of 36.1 mL to 31.3 mL within two months, a loss of about 4.8 mL. By eight months, the average reduction reached 6.2 mL, or roughly 17% of the original volume. After that point, shrinkage tends to plateau.
When hormone therapy (also called androgen deprivation therapy) is given before radiation, the numbers change significantly. Hormone therapy on its own causes a 25% to 50% reduction in prostate volume by cutting off the testosterone that prostate tissue depends on for growth. Studies consistently report 30% to 40% tumor volume reduction from the hormonal component alone. This is one reason doctors often prescribe several months of hormone therapy before starting radiation: a smaller prostate means the radiation field can be tighter, which allows higher doses to the tumor with less damage to surrounding healthy tissue.
Timeline of Changes
The bulk of radiation-related shrinkage happens in the first one to two months after treatment. In MRI-based studies, the largest measurable drop in volume occurs during this early window. A second, smaller phase of shrinkage continues over the following several months, with the gland losing an additional 1 to 2 mL between roughly months two and eight. By about 14 months post-treatment, measurable shrinkage typically stops.
If you’re receiving hormone therapy alongside radiation, the timeline shifts earlier. Three months of hormone therapy before radiation can decrease prostate volume by 30% to 50% before the first radiation session even begins. Some treatment plans use up to 10 months of hormone therapy before starting radiation, which produces even greater reduction upfront.
Effect on Urinary Symptoms
For men who had urinary problems before treatment, particularly difficulty urinating or frequent urination caused by an enlarged prostate pressing on the urethra, shrinkage can bring real relief. Research tracking symptom scores over time found that men who started with moderate to severe urinary symptoms saw the most improvement after combined radiation and hormone therapy. The shrinkage physically reduces the pressure on the urethra, making it easier to urinate.
Men who had only mild symptoms before treatment tended to see smaller improvements, likely because their prostates were already relatively small and weren’t causing much obstruction. It’s worth noting that radiation can temporarily worsen urinary symptoms during and shortly after treatment due to inflammation, even as the gland is beginning to shrink. This irritation usually settles within weeks to a few months.
Radiation Is Not Used to Treat BPH
Although radiation does shrink the prostate, it is not a treatment for benign prostatic hyperplasia (BPH), the non-cancerous enlargement that affects most men as they age. Radiation therapy is reserved for prostate cancer. The long-term tissue changes it causes, including reduced blood flow, fibrosis, and potential bladder irritation, make it far too aggressive for a condition that has safer, more targeted options.
For BPH, treatments range from medications that relax or shrink prostate tissue to minimally invasive procedures. Prostatic artery embolization, for example, reduces blood flow specifically to the prostate to shrink it without radiation’s side effects. If you’re looking for ways to reduce prostate size for urinary relief and you don’t have cancer, radiation would not be part of that conversation.
Long-Term Tissue Changes
The shrinkage from radiation is essentially permanent. Over years, radiated prostate tissue continues to become more fibrous and less cellular. Blood vessels in the area develop permanent narrowing, leaving the tissue in a state sometimes described as low in blood flow, low in cells, and low in oxygen. This is a normal and expected consequence of pelvic radiation.
These tissue changes can occasionally cause late side effects that appear months or years after treatment. The most common is mild blood in the urine from fragile, dilated blood vessels that develop in the bladder lining. Less commonly, the bladder wall itself can become stiffer over time, which may reduce its capacity and cause more frequent urination. Severe complications like significant bleeding or major bladder changes are uncommon but can occur, particularly at higher radiation doses. Your treatment team will monitor for these changes during follow-up visits, typically using PSA blood tests, imaging, and symptom questionnaires.
How Shrinkage Is Tracked
Doctors measure prostate volume using MRI, which provides the most accurate three-dimensional picture of the gland. In studies and clinical practice, MRI scans are taken before treatment and at follow-up intervals, often around two months, six to eight months, and again around a year or later. The volume is calculated from the dimensions of the gland on imaging and compared to the pre-treatment baseline.
In routine follow-up for prostate cancer, however, your doctor may rely more on PSA levels than on repeated imaging to track how well treatment is working. A declining PSA after radiation is a strong signal that the cancer is responding. MRI is more likely to be ordered if PSA levels aren’t dropping as expected or if new symptoms develop. The physical shrinkage of the gland, while real and measurable, is typically less important to your oncologist than whether the cancer cells themselves have been eliminated.